Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1226 • ACR Convergence 2020
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
Roxanne Cooksey¹, Sinead Brophy¹, Muhammad Azizur¹, Jonathan Kennedy¹ and Ernest Choy², ¹Swansea University, Swansea, Wales, United Kingdom, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics. Etanercept biosimilar,…
Abstract Number: 1338 • ACR Convergence 2020
Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
Atlas Mashayekhi Sardoo¹, Daniel Sobral², Lucia Domingues³, Santiago Rodrigues-Manica⁴, Rita Pinheiro Torres⁴, Agna Neto⁵, Ana Filipa Fernandes⁶, Patricia Alves⁷, Julia Costa⁶, Ana Rita Grosso², Celso Cunha⁸, Jaime Branco⁹ and Fernando M Pimentel-Santos⁴, ¹3. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ²Faculty of Science and Technology, Universidade Nova de Lisboa, Caparica, Portugal, ³NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal, ⁴CHLO, Hospital Egas Moniz, Lisbon, Portugal, ⁵1. Rheumatology Department, Hospital Central do Funchal, Madeira, Portugal. 2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, ⁶ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Oeiras, Portugal, ⁷IBET - Institute of Experimental Biology and Technology, Oeiras, Portugal, ⁸Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa, Lisbon, Portugal, ⁹2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Early diagnosis of axial Spondyloarthritis (axSpA) represents a major clinical challenge nowadays. Increasing evidence has determined that early diagnosis, prompt treatment initiation and early…
Abstract Number: 1849 • ACR Convergence 2020
Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study
Jesus Miguens Blanco¹, Uma Selvarajah¹, Zhigang Lui¹, Benjamin Mullish¹, James Alexander¹, Julie McDonald², Sonya Abraham¹ and Julian Marchesi¹, ¹Imperial College London, London, United Kingdom, ²Imperial College London, London
Background/Purpose: Perturbations of the gut microbiota have been associated with Psoriatic Arthritis (PsA), a chronic inflammatory disease. We aim to test the microbiome-metabolic interface of…
Abstract Number: 1884 • ACR Convergence 2020
Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Jean Liew¹, Maria Castillo², Ethan Zaccagnino², Patricia Katz³, Nigil Haroon⁴ and Lianne Gensler⁵, ¹University of Washington, Seattle, WA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Response to the global coronavirus disease (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to how people go about their daily lives.…
Abstract Number: 2024 • ACR Convergence 2020
Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial
Walter Maksymowych¹, Mikkel Østergaard², Robert Landewé³, William Barchuk⁴, Ke Liu⁴, Chantal Tasset⁵, Leen Gilles⁵, Thijs Hendrikx⁶, Robin Besuyen⁶ and Xenofon Baraliakos⁷, ¹University of Alberta, Edmonton, AB, Canada, ²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos BV, Leiden, Netherlands, ⁷Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…
Abstract Number: 0369 • ACR Convergence 2020
Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs
Atul Deodhar¹, Xenofon Baraliakos², Iain McInnes³, Kurt de Vlam⁴, Louis Bessette⁵, Anna Maniccia⁶, Ralph Lippe⁷, Christopher Saffore⁶, Tianming Gao⁶, In-Ho Song⁶ and Andrew Östör⁸, ¹Oregon Health & Science University, Portland, OR, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ³Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ⁵Laval University, Quebec, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Pain is a debilitating symptom of ankylosing spondylitis (AS) and negatively impacts patient (pt) lives. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor engineered for…
Abstract Number: 1303 • ACR Convergence 2020
Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort
Ulrich Weber¹, Raj Carmona², James Yeung³, Jon Chan⁴, Liam Martin⁵, Ariel Masetto⁶, Stephanie Keeling⁷, Olga Ziouzina⁵, Sherry Rohekar⁸, Rana Dadashova⁹, Joel Paschke⁹, Amanda Carapellucci⁹, Robert G Lambert¹⁰, Walter Maksymowych⁷ and Sibel Aydin¹¹, ¹University of South Denmark, Odense, Denmark, ²St. Joseph's Healthcare, Hamilton, ON, Canada, ³James Yeung Rheumatology, Vancouver, BC, Canada, ⁴Artus Health Clinic, Vancouver, BC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Lawson Health Research Institute, London, ON, Canada, ⁹CARE Arthritis, Edmonton, AB, Canada, ¹⁰University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ¹¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…
Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Runsheng Wang¹, Abhijit Dasgupta² and Michael Ward³, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²NIAMS, Bethesda, ³National Institutes of Health, Bethesda, MD
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…
Abstract Number: 1858 • ACR Convergence 2020
Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden
Kristina Lejon¹, Urban Hellman², Lan Do², Anjani Kumar² and Helena Forsblad-d'Elia³, ¹Department of Clinical microbiology, Infection and Immunology, Umeå University, Umeå, Sweden, ²Department of Public Health and Clinical Medicine, Rheumatology, Umeå, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Vasterbottens Lan, Sweden
Background/Purpose: Increased levels of TH17 and TH22 as well as TC17 and TC22 cells have previously been associated with ankylosing spondylitis (AS). The correlation between…
Abstract Number: 1885 • ACR Convergence 2020
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
Emilce Schneeberger¹, Gustavo Citera², Dario Ponce de Leon³, Annette Szumski⁴, Kenneth Kwok⁵, Mariel Cutri⁶ and Maxime Dougados⁷, ¹Department of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³PFIZER, LIMA, Peru, ⁴Syneos Health, Princeton, ⁵Pfizer, New York, NY, ⁶Pfizer, Buenos Aires, Argentina, ⁷Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…
Abstract Number: 0371 • ACR Convergence 2020
Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States
Theresa Hunter¹, Michael Grabner², Keith Isenberg³, Mingyang Shan⁴, Chia-Chen Teng², Jeffrey Lisse⁴ and Jeffrey R Curtis⁵, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Anthem, Inc, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year from biologic initiation among ankylosing spondylitis (AS)…
Abstract Number: 1305 • ACR Convergence 2020
Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Approximately 30% of HLA-B27(+) patients with ankylosing spondylitis (AS) have one or more episodes of acute anterior uveitis (AAU), a condition that is also…
Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Mark Siderius¹, Freke Wink¹, Anneke Spoorenberg¹ and Suzanne Arends¹, ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
Abstract Number: 1862 • ACR Convergence 2020
Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years
Muhammad Khan¹, Sjef van der Linden², Peter Villiger³, Zhixiu Li⁴, Mohammad Khan⁵, Heinz Baumberger⁶, Hermine Zandwijk⁷ and Matthew Brown⁸, ¹Case Western Reserve University, Cleveland OH, Westlake, OH, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁴Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁵Kent State University, Kent, OH, ⁶Retired, Flims, Tajikistan, ⁷Retired, Mortroux, Belgium, ⁸Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: To investigate the recurrence rate (RR) of ankylosing spondylitis (AS) over a lifespan, probands with clinically diagnosed AS and their first-degree relatives (FDRs) were…
Abstract Number: 1889 • ACR Convergence 2020
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Yvette Farran¹, Alexis Ogdie², John Reveille³ and Mark Hwang⁴, ¹McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, University of Texas, Houston, TX, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].